Provided by Tiger Trade Technology Pte. Ltd.

Sandridge Energy Inc.

13.99
-0.3700-2.58%
Post-market: 13.990.00000.00%19:30 EDT
Volume:321.22K
Turnover:4.51M
Market Cap:514.46M
PE:6.24
High:14.29
Open:14.29
Low:13.88
Close:14.36
52wk High:18.45
52wk Low:11.10
Shares:36.77M
Float Shares:36.36M
Volume Ratio:0.76
T/O Rate:0.88%
Dividend:0.49
Dividend Rate:3.50%
EPS(TTM):2.24
EPS(LYR):1.90
ROE:16.22%
ROA:7.14%
PB:0.95
PE(LYR):7.36

Loading ...

Lifedrink Completes Acquisition Of SD Next, SD Bottlers Via Unit

MT Newswires Live
·
Apr 01

SD Guthrie's Cost Pressures Likely Offset by Higher Crude Palm Oil Prices -- Market Talk

Dow Jones
·
Mar 30

Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026

GlobeNewswire
·
Mar 27

SD Guthrie Releases February Production Report

MT Newswires Live
·
Mar 26

Enercom Announces Initial List of Presenting Companies for the 31St Annual Energy Investment Conference to Be Held August 17-19, 2026, in Denver, Colorado

THOMSON REUTERS
·
Mar 19

SD Guthrie's Outlook May Remain Stable Amid Middle East Conflict -- Market Talk

Dow Jones
·
Mar 17

SandRidge Energy downgraded to Sell from Buy at Freedom Capital

TIPRANKS
·
Mar 10

TA Securities Upgrades SD Guthrie to Buy from Sell; Price Target is MYR6.33

MT Newswires Live
·
Mar 09

SandRidge Energy Q4 Adj. EPS $0.34 Misses $0.37 Estimate, Sales $39.400M Miss $43.700M Estimate

Benzinga Earnings
·
Mar 05

SandRidge posts Q4 net income of USD 21.6 million up USD 4.1 million

Reuters
·
Mar 05

SandRidge Energy Q4 Adjusted EPS USD 0.34

THOMSON REUTERS
·
Mar 05

SandRidge Energy, Inc. Announces Financial and Operating Results for the Quarter and Year Ended December 31, 2025, $0.12 per Share Cash Dividend, and 2026 Guidance

THOMSON REUTERS
·
Mar 05

SandRidge Energy Inc. Updates Financial Calendar

Reuters
·
Mar 03

Celldex presents new data from Phase 2 ColdU, SD Open Label Extension

TIPRANKS
·
Mar 02

Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

GlobeNewswire
·
Mar 01

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

GlobeNewswire
·
Feb 28

SD Guthrie's Key Catalysts Appear Priced In -- Market Talk

Dow Jones
·
Feb 26